Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2B Single-site, Open-label, Nonrandomized Study Evaluating the Efficacy of Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma

NCT02306850 is registered in ClinicalTrials.gov with St. Louis University as lead sponsor.

NCT NCT02306850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02306850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2B Single-site, Open-label, Nonrandomized Study Evaluating the Efficacy of Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Lead sponsor
St. Louis University
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2015
Completion date
June 8, 2018
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, metastatic melanoma, stage iii melanoma, stage iv melanoma, unresectable malignant neoplasm